SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BrokeCoin is a meme-meets-utility cryptocurrency project operating under the ethos of Transparency, Community, and Respect. Formally registered as an LLC in Wyoming, USA, BrokeCoin is building an expansive ecosystem that combines light-hearted spirit of meme culture with real-world crypto utilities—spanning gaming, staking, NFTs, web services, and an e-commerce platform. Brokecoin believes in developing useful and interesting meme-inspired utilities to both service the crypto industry, and generate value for holders.

Brokecoin

Brokecoin is trending as the community rallies around ongoing development and utilities, including staking and play-to-earn games, while highlighting its resilience as a long-term project. Community members are excited about upcoming burns and the potential for significant growth. The focus remains on building a strong foundation and achieving new all-time highs.

SSgA Active Trust - SPDR S&P 500 ETF Trust

SPY is trending as traders anticipate the CPI release, with community members discussing potential market reactions and hedging strategies. Talk of terminated trade negotiations with Canada and their potential impact are circulating. Overall market sentiment seems cautiously bullish, with some bracing for volatility.

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

SMCI is trending due to a lowered Q1 revenue outlook, despite reaffirming strong full-year guidance and highlighting over $12 billion in new design wins for Q2 delivery. While some investors express frustration with management's forecasting, others view the dip as a buying opportunity, citing robust demand for AI solutions and confidence in long-term growth. Community discussions center on the significance of the delayed revenue and the potential for a rebound driven by strong Q2 performance.

Avantis is the largest RWA perps DEX in DeFi, built on and backed by Base. Avantis allows users to trade crypto and real-world assets (RWAs), including FX, commodities, indices, and equities. Backed by Pantera and Coinbase, Avantis is the largest DEX on Base by volumes, and brings institutional-grade products to DeFi, letting users trade with up to 500x leverage in a transparent, permissionless environment.  Avantis is best known for launching zero-fee perpetuals (ZFP) — a first-of-its-kind primitive where traders only pay fees if they profit. They've also brought leveraged RWAs onchain. This has driven explosive growth: over $20B+ in cumulative volume and 15M+ run-rate revenues since Febrruary 2024.

Avantis

$AVNT is trending as the community discusses its recent price action and potential.  Traders are actively debating its volatility, entry points, and whether it can sustain its upward momentum.  Some believe its association with Coinbase and its position as a perp dex could drive future growth.

$BALLIN is the perfect meme for everyone showing up every single day.  To be BALLIN, you gotta B-All-In.  The meaning to B All In doesn't only apply to the funds you invest.  It's about dedication.   The countless hours of research.   The endless raiding and working for your bags.  Not knowing how to quit while everyone is telling you you're wrong.  It's about believing in something.  Keep $BALLIN

B All In

B All In ($BALLIN) is gaining attention, with community members highlighting its availability on Phantom Wallet and touting potential gains. The conversation centers around the idea of a "balling" lifestyle and the opportunity for early entry. However, some users are also expressing skepticism, labeling it a scam.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

QQQ is trending amid discussions about potential market manipulation and its seemingly unstoppable upward momentum, with community members debating whether a pullback is due. Speculation is high around upcoming CPI data and its potential impact, while some traders point to a disconnect between market performance and underlying fundamentals. Talk of a Trump-Xi meeting is also influencing sentiment.

SSgA Active Trust - SPDR Dow Jones Industrial Average ETF

The SPDR Dow Jones Industrial Average ETF ($DIA) is trending due to renewed US-China trade tensions following President Trump's threat of increased tariffs, sparking market volatility and a sell-off. Community discussions revolve around the potential economic impact and whether this is a buying opportunity or the start of a larger correction. Investors are also monitoring upcoming earnings reports and potential shifts in Federal Reserve policy in response to these developments.

Vertiv Holdings Co. engages in the design, manufacture, and service of critical digital infrastructure technology for data centers, communication networks, and commercial and industrial environments. It also offers power management products, switchgear and busbar products, thermal management products, integrated rack systems, modular solutions, and management systems for monitoring and controlling digital infrastructure. It operates through the following geographical segments: Americas, Asia Pacific, and Europe, Middle East, and Africa (EMEA). The Americas segment offers products and services sold for applications within the data center, communication networks, and commercial and industrial markets in North America and Latin America. The Asia Pacific segment includes products and services sold for applications within the data center, communication networks, and commercial or industrial markets throughout Greater China, Australia and New Zealand, Southeast Asia, and India. The EMEA segment focuses on products and services sold for applications within the data center, communication networks, and commercial and industrial markets in Europe, Middle East, and Africa. The company was founded in 1946 and is headquartered in Columbus, OH.

Vertiv Holdings Co - Ordinary Shares - Class A

Vertiv Holdings Co

Vertiv is trending due to a combination of strong Q3 earnings, raised guidance, and positive analyst ratings, all driven by the increasing demand for AI infrastructure and data centers. The community is discussing the company's growth potential, strategic acquisitions, and its partnership with NVIDIA. Some investors express frustration with price action, while others remain bullish on the long-term prospects of Vertiv in the AI space.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

META is trending as investors discuss the potential impact of AI developments and infrastructure investments, including a new data center project. Community members are weighing the stock's valuation and growth prospects ahead of upcoming earnings, with some anticipating a significant move. Discussions also involve technical analysis, potential partnerships, and the competitive landscape in the AI sector.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending following its latest earnings report, which beat expectations and highlighted the company's focus on AI and foundry services. The community is discussing the potential for a significant rise, with some targeting $50 and beyond, driven by renewed confidence in Intel's growth prospects. Investors are also considering Intel's strategic importance and the impact of government support for domestic semiconductor manufacturing.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO TransCode Therapeutics presents preliminary data from its completed...

TransCode Therapeutics, Inc. (RNAZ) on Wednesday said that it has entered into a definitive agreement to acquire privately-held biotech firm Polynoma LLC from CK Life Sciences.The company also <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/transcode-therapeutics-rnaz-announces-the-acquisition-of-polynoma-and-a-25-million-strategic-financing-by-a-subsidiary-of-ck-life-sciences-to-form-a-first-in-class-unique-immuno-oncology-and-metastatic-prevention-oncology-compa-302578286.html">announced</a> a $25 million investment from CK Life Sciences, expected to be used to advance the clinical development of its lead microRNA asset called TTX-MC138 into a mid-stage clinical trial. The candidate is believed to be a master regulator of metastatic cancer across multiple indications.Shares of the company soared 55% in the pre-market session at the time of writing. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/RNAZ">RNAZ stock</a> jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘normal’ to ‘high’ levels.Polynoma is developing a late-stage candidate called seviprotimut-L, a vaccine aimed at melanoma patients who have limited options in stage IIB and IIC.“Between the two programs, we see a unique potential to augment seviprotimut-L's focus with our microRNA lead program, TTX-MC138, by addressing the micrometastases in stage IIB and IIC melanoma patients," TransCode’s new CEO, Philippe Calais, said.TransCode on Wednesday also announced that Calais has been appointed as the company CEO while remaining Chairman of the Board of Directors. Tom Fitzgerald stepped down as Interim CEO but remains CFO, it added.While there are no other changes to TransCode’s executive team, the company expects to retain several finance, development, and manufacturing professionals from Polynoma, it added.RNAZ stock is down by 87% this year and by 97% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/stifel-hikes-price-target-on-tesla-after-fsd-v14-roll-out/ch6EKRbR3i9">Stifel Hikes Price Target On Tesla After FSD V14 Roll Out, Reiterates Hopes In Robotaxi</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

TransCode Therapeutics To Acquire Polynoma, Receive $25M Investment To Advance Key Asset

The $25 million is expected to be used to advance the clinical development of its lead microRNA asset into a mid-stage clinical trial. 

Equity

The $25 million is expected to be used to advance the clinical development of its lead microRNA asset into a mid-stage clinical trial. 


Shares of TransCode Therapeutics Inc surged nearly 39% on Thursday after the company announced encouraging progress in its Phase 1a clinical trial of TTX-MC138, an experimental therapy targeting metastatic cancer.TTX-MC138 is a first-in-class therapeutic candidate designed to inhibit microRNA-10b (miR-10b), a genetic target believed to play a critical role in the emergence and progression of several metastatic cancers.&nbsp;According to TransCode, 13 patients have been treated with TTX-MC138 across four dose levels ranging from 0.8 mg/kg to 4.8 mg/kg.&nbsp;Eight patients remain on study, receiving additional doses during each 28-day treatment cycle, and two patients have been on therapy for approximately seven months with stable disease observed.No dose-limiting toxicities or significant safety concerns have been reported in the trial. Preliminary pharmacokinetic and pharmacodynamic data also align with earlier preclinical and Phase 0 findings.&nbsp;The results support advancing to the planned Phase 1b dose expansion, where researchers will further evaluate safety and early anti-tumor signals.The company’s financial position has been a key focus. As of April 2025, TransCode reported a cash balance of $5.81 million, with total liabilities exceeding assets by $2.02 million.&nbsp;Recent fundraising has helped shore up liquidity, including a $10.05 million registered direct offering in March 2025 and a $7.19 million equity raise in January.&nbsp;Last week, H.C. Wainwright lowered its price target on TransCode to $10 from $20 while maintaining a ‘Buy’ rating, according to The Fly.The firm cited recent equity raises as the reason for the revision but noted that its updated model assumes current funds are sufficient to support operations into 2026.Retail enthusiasm was evident on Stocktwits as sentiment was described as ‘extremely bullish,’ with message volume reaching ‘extremely high’ levels.&nbsp;Traders speculated on further upside, with some suggesting the stock could soon surpass the $1 mark and noting bullish chart patterns that could support another leg higher in after-hours trading.<stembedurl>https://stocktwits.com/ProfessorDman1/message/613317226</stembedurl><stembedurl>https://stocktwits.com/al_fred/message/613270466</stembedurl>Despite Thursday’s sharp rebound, TransCode shares remain down 84% year-to-date, far underperforming the broader market.&nbsp;By comparison, the Nasdaq is down 1.7%, while the Dow and S&amp;P 500 have declined 3.9% and 4.5%, respectively, over the same period.For updates and corrections, email newsroom[at]stocktwits[dot]com.

An electronic board displays information on recent fluctuations of market indices at the B3 Stock Exchange in Sao Paulo, Brazil, on April 7, 2025. (Photo by Cris Faga/NurPhoto via Getty Images)

TransCode Stock Rallies On Promising Metastatic Cancer Drug Trial: Retail Sees More Upside

TransCode Therapeutics shares surged nearly 39% after reporting promising Phase 1a trial results for its metastatic cancer drug TTX-MC138, with strong retail interest and no major safety concerns. 

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics, Inc. Announces Results of Special Meeting TransCode Therapeutics, Inc. Announces Results of Special Meeting PR Newswire BOSTON, Feb. 25, 2025 BOSTON, Feb. 25, 2025...

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead...

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and...

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead...

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing...

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial TransCode Therapeutics...

Why TransCode Therapeutics (RNAZ) Stock Is Getting Hammered

TransCode Therapeutics shares are trading lower by 40.6% during Monday's session. The company disclosed plans for a potential reverse stock split in an open letter to its shareholders.
read more...

TransCode Therapeutics, Inc. engages in the development and commercializing of diagnostics and therapeutics for the detection and treatment of cancer. The company was founded by Robert Michael Dudley, Zdravka Medarova, and Anna Moore in January 2016 and is headquartered in Boston, MA.

RNAZ
TransCode Therapeutics Inc

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest RNAZ News

RNAZTransCode Therapeutics Inc